Maternal serum biomarkers for risk assessment in gestational diabetes. A potential universal screening test to predict GDM status

• Published in: Indian journal of endocrinology and metabolism Vol. 19; no. 1; pp. 155 - 159
• Main Authors: Nagalla, Srinivasa R, Snyder, Caryn K, Michaels, John E, Laughlin, Mary J, Roberts, Charles T, Balaji, Madhuri, Balaji, V, Seshiah, V, Rao, Paturi V
• Format: Journal Article
• Language: English
• Published: India Medknow Publications and Media Pvt. Ltd 01.01.2015; Medknow Publications & Media Pvt. Ltd; Medknow Publications & Media Pvt Ltd; Wolters Kluwer Medknow Publications
• Subjects: Biological markers; Brief Communication; Diabetes in pregnancy; Diagnosis; Gestational diabetes; Glucose tolerance tests; glycosylated fibronectin; maternal serum biomarker; Physiological aspects; Risk factors; India; glycosylated fibronectin; maternal serum biomarker; Gestational diabetes
• ISSN: 2230-8210; 2230-9500
• DOI: 10.4103/2230-8210.140226

The prevalence of gestational diabetes mellitus (GDM) is increasing because of the worldwide obesity/diabetes epidemic. The complications of untreated GDM affect both the mother and baby and include complications during pregnancy as well as increased risk of subsequent type-2 diabetes in mothers and offspring. Standard tests for hyperglycemia in diabetes, such as fasting glucose and hemoglobin (HbA1c), are currently not recommended for GDM screening. Instead, an oral glucose tolerance test is specified, which is invasive, time-consuming, and not easily accessible to many at-risk populations. In this study, we describe a multi-analyte maternal serum profile test that incorporates novel glycoprotein biomarkers and previously described GDM-associated markers. In screening for GDM by multi-analyte panel, the detection rate was 87% at a false-positive rate of 1%.